Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation

BCL-2 family proteins are frequently aberrantly expressed in mantle cell lymphoma (MCL). Recently, the BCL-2-specific inhibitor venetoclax has been approved by the US Food and Drug Administration for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). In MCL, venetoclax has shown pr...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Haematologica (Roma) Ročník 108; číslo 3; s. 797 - 810
Hlavní autoři:	Thus, Yvonne J., De Rooij, Martin F.M., Swier, Nathalie, Beijersbergen, Roderick L., Guikema, Jeroen E.J., Kersten, Marie-José, Eldering, Eric, Pals, Steven T., Kater, Arnon P., Spaargaren, Marcel
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Italy Fondazione Ferrata Storti 01.03.2023 Ferrata Storti Foundation
Témata:	Adult Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Bridged Bicyclo Compounds, Heterocyclic - pharmacology Bridged Bicyclo Compounds, Heterocyclic - therapeutic use Casein Kinase II - genetics Casein Kinase II - metabolism Cell Line, Tumor Down-Regulation Humans Lymphoma, Mantle-Cell - drug therapy Lymphoma, Mantle-Cell - genetics Lymphoma, Mantle-Cell - metabolism Myeloid Cell Leukemia Sequence 1 Protein - metabolism Non-Hodgkin Lymphoma Proto-Oncogene Proteins c-bcl-2
ISSN:	0390-6078, 1592-8721, 1592-8721
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!